Bull&Bear | Eason Tech Soars 168% Amid Bullish Market; Deckers Outdoor Drops 20% in Bearish Turn

In the world of bullish stocks, Eason Technology Co. experienced a significant increase of 168% in its share price. This remarkable rise was driven by the company's release of an optimistic financial report, capturing the attention of investors.

Cipher Mining (CIFR) marked a notable gain of 21.91%, continuing a three-day upward trend with a total increase of 27.62% over this period. Analysts have maintained a 'buy' rating for Cipher Mining, setting a target price of $11, indicating positive sentiment towards the stock's future performance.

SELLAS Life Sciences (SLS) also saw a rise of 21.80%, maintaining a three-day upward momentum with an overall increase of 38.46%. The company announced favorable results from its phase three trials, contributing to the positive market reaction.

LiveOne (LVO) observed a 20.83% increase, continuing a two-day upward trend with a 26.09% rise over these days. The collaboration between LiveOne and Tesla exceeded expectations, resulting in a surge of users to over 600,000, marking a 33% growth since January 1st.

Viavi Solutions (VIAV) experienced a rise of 20.52%, maintaining a four-day upward trend with a total increase of 24.00%. The company's recovery efforts are progressing well, and analysts have upgraded the stock rating, forecasting stronger results for 2025.

On the bearish side, Deckers Outdoor (DECK) suffered a decline of 20.44%. The stock is testing critical levels, prompting market concerns as investors remain uncertain about its future trajectory.

Beazer Homes (BZH) saw a drop of 20.04% as sales momentum slowed down in November and December, affecting investor sentiment negatively.

Exodus Movement (EXOD) experienced an 18.61% decrease, continuing a two-day downward trend with a cumulative 44.05% drop over these days. Despite this, analysts have maintained a 'buy' rating for Exodus Movement, with a target price of $50, reflecting potential optimism for future performance.

Diginex (DGNX) saw a decline of 16.45% following its initial public offering, contributing to negative sentiment surrounding the stock.

MBX Biosciences (MBX) faced a 14.00% decrease, potentially impacted by the company's announcement regarding the initial results of phase one single and multiple ascending dose trials of MBX 1416, which drew market attention.